Core Viewpoint - Aurinia Pharmaceuticals has undergone a significant leadership change with a complete overhaul of its C-suite, leading to a rally in its stock and speculation about potential acquisitions [1]. Group 1: Leadership Changes - Kevin Tang has been appointed as the new CEO, replacing Peter Greenleaf, who led the company for seven years [2]. - Alongside Tang, Ryan Cole has been appointed COO, Michael Hearns as CFO, and Thomas Wei as CSO, all of whom have connections to Tang Capital Management [4]. - Tang has a history of successfully leading companies through exits, including Ardea Biosciences and La Jolla Pharmaceutical [2]. Group 2: Market Reaction - Following the announcement, Aurinia's stock rose by 3.9%, closing at 14.56, and is consolidating with a buy point at 16.54 [3]. - The stock briefly surpassed its 50-day moving average, indicating positive market sentiment [3]. Group 3: Analyst Perspectives - RBC Capital Markets analyst Douglas Miehm views the leadership changes as "slightly positive" for the stock, noting Tang's ownership of approximately 9% of Aurinia's shares aligns his interests with those of shareholders [5]. - Miehm maintains a sector perform rating with a price target of 15, while acknowledging the near-term executive risk due to the simultaneous departure of four senior officers [6]. - Leerink Partners analyst Joseph Schwartz expressed interest in the new team's plans for enhancing shareholder value, given the company's positive cash flow [3][4].

Core Viewpoint - Aurinia Pharmaceuticals is experiencing significant stock momentum, attributed to a leadership transition and ongoing progress in its product pipeline [1][2][3]. Group 1: Leadership Changes - Kevin Tang has been appointed as the new CEO, succeeding Peter Greenleaf, who will continue as a consultant during the transition [2]. - The market reacted positively to the leadership change, indicating confidence in Aurinia's operational strength [3]. - Several executive appointments were made alongside the CEO change, including Ryan Cole as COO, Michael Hearne as CFO, and Thomas Wei as CSO, suggesting stability within the leadership team [4]. Group 2: Product Focus - Aurinia's primary product, Lupkynis, is gaining traction as a standard therapy for lupus nephritis, which is crucial for the company's commercial growth [3][5]. - Aritinercept is highlighted as a potential long-term catalyst for the treatment of autoimmune diseases, indicating ongoing pipeline development [5]. Group 3: Stock Performance - Aurinia Pharmaceuticals' stock (AUPH) saw a 5.06% increase, reaching $14.74, reflecting positive market sentiment [7]. - The Relative Strength Index (RSI) for AUPH has fluctuated between neutral and overbought levels, indicating varying momentum in the stock's performance [6].

Core Insights - Aurinia Pharmaceuticals Inc reported strong fourth-quarter earnings, with adjusted earnings of 26 cents per share, surpassing analysts' expectations of 22 cents and significantly up from 1 cent a year earlier [2] - The company raised its revenue outlook for 2026, projecting total revenue between $315 million and $325 million, indicating an 11% to 15% growth, although this is slightly below the Wall Street consensus of approximately $327 million [3] Group 1: Financial Performance - Fourth-quarter revenue increased to $77.1 million from $59.9 million, exceeding the forecast of $74.8 million [2] - Aurinia repurchased 12.2 million shares for $98.2 million, ending the year with $398 million in cash, equivalents, and investments [3] Group 2: Future Outlook - The company expects net product sales of Lupkynis to be between $305 million and $315 million for 2026 [3] - CEO Peter Greenleaf emphasized the goal of increasing Lupkynis adoption and advancing the autoimmune candidate aritinercept, which is entering additional clinical studies in 2026 [4] Group 3: Market Reaction - Despite the positive earnings and growth outlook, Aurinia's stock is experiencing bearish pressure, with shares down 3.15% to $13.98 at the time of publication [6] - The stock's decline is attributed to a conservative revenue outlook and the impact of a one-time tax benefit that inflated 2025 profits, despite the company achieving double-digit sales growth [4]

Core Insights - Aurinia Pharmaceuticals reported significant growth in revenue and net income for the full year 2025, driven primarily by its lupus nephritis therapy, LUPKYNIS [4][6][7] Financial Performance - Total revenue for the full year 2025 was $283.1 million, a 20% increase from $235.1 million in 2024; excluding a one-time $10 million milestone payment, revenue increased by 26% year over year [1][6] - Full-year net product sales of LUPKYNIS reached $271.3 million, up 25% from $216.2 million in 2024 [1] - In Q4 2025, net income surged to $210.8 million from $1.4 million in the same quarter of the previous year, largely due to a $175.1 million income tax benefit [2][6] - Diluted earnings per share for 2025 were $2.07, up from $0.04 in 2024 [7] Revenue Breakdown - Q4 2025 revenue was $77.1 million, a 29% increase from $59.9 million in Q4 2024; net product sales of LUPKYNIS in the quarter were $74.2 million, also up 29% [3][6] - Management provided guidance for 2026, expecting total revenue of $315 million to $325 million, representing 11% to 15% growth compared to 2025 [9] Pipeline and Clinical Development - Aurinia has initiated clinical development of aritinercept, a dual BAFF/APRIL inhibitor, with two studies planned for H1 2026 [5][16] - The pediatric VOCAL study was terminated due to recruitment challenges, and the company plans to negotiate with the FDA regarding pediatric commitments in lupus nephritis [18] Commercial Dynamics - The company is seeing growth in patient adherence and consistency in the mix of business, with a favorable prescriber mix leaning slightly towards rheumatology [11][12] - Management noted that guideline-driven improvements in diagnostics and treatment for lupus nephritis have room for expansion, with current practices not fully aligning with recommended guidelines [13][14] Competitive Landscape - Despite the approval of Gazyva for lupus nephritis, Aurinia has not observed a near-term impact on its business performance [14] - LUPKYNIS is positioned competitively due to its efficacy in reducing proteinuria rapidly compared to other therapies [15]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $77.1 million, up 29% from $59.9 million in Q4 2024 [4] - Net product sales of LUPKYNIS for Q4 2025 were $74.2 million, up 29% from $57.6 million in Q4 2024 [4] - Net income for Q4 2025 was $210.8 million, up 14,957% from $1.4 million in Q4 2024, primarily due to a significant income tax benefit [4] - Diluted earnings per share for Q4 2025 was $1.53, up 15,200% from $0.01 in Q4 2024 [5] - Total revenue for the year ended December 31, 2025, was $283.1 million, up 20% from $235.1 million in 2024 [6] - Net income for the year ended December 31, 2025, was $287.2 million, up 4,852% from $5.8 million in 2024 [6] Business Line Data and Key Metrics Changes - Net product sales of LUPKYNIS for the year ended December 31, 2025, were $271.3 million, up 25% from $216.2 million in 2024 [6] - Cash flows from operating activities for Q4 2025 were $45.7 million, up 52% from $30.1 million in Q4 2024 [5] - Cash flows from operating activities for the year ended December 31, 2025, were $135.7 million, up 206% from $44.4 million in 2024 [7] Market Data and Key Metrics Changes - The company expects net product sales of $305 million to $315 million for 2026, representing a 12%-16% increase compared to 2025 [3][8] - The company repurchased 12.2 million common shares for $98.2 million, reducing fully diluted shares outstanding from 149.8 million to 139.7 million [7] Company Strategy and Development Direction - The company is focused on the growth of LUPKYNIS while advancing the clinical development of aritinercept, a novel biologic for autoimmune diseases [9][10] - The strategy includes leveraging data on the efficacy of LUPKYNIS and promoting early diagnosis and treatment of lupus nephritis [14][27] - The company aims to change the treatment paradigm by emphasizing the importance of early identification and aggressive treatment of proteinuria [14][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued growth of LUPKYNIS, citing strong adherence and persistency among patients [24] - The management acknowledged the competitive landscape but emphasized the unique benefits of LUPKYNIS, particularly its speed in reducing proteinuria [36][38] - The company does not expect significant contributions from international markets compared to the U.S. due to varying pricing and reimbursement structures [42][43] Other Important Information - The company terminated the phase 3 VOCAL study due to recruitment challenges and plans to negotiate with the FDA regarding pediatric commitments [16][17] - Management is optimistic about the potential of aritinercept and plans to initiate clinical studies in additional autoimmune diseases in 2026 [10][22] Q&A Session Summary Question: Guidance for 2026 seems conservative; what are the underlying assumptions? - Management explained that the guidance is based on historical growth patterns and current market conditions, with no extraordinary trends observed in early 2026 [12][15] Question: Clarification on the termination of the VOCAL study and FDA's stance? - The study was terminated due to recruitment difficulties, and management plans to discuss pediatric commitments with the FDA [16][17] Question: Update on AURINIAcept development? - Management confirmed that updates will be provided in the second quarter of 2026, with no preferential indication currently identified [20][50] Question: Impact of Gazyva's approval on LUPKYNIS? - Management stated that there has been no immediate impact on LUPKYNIS sales, and the guidance incorporates various competitive factors [34][35] Question: Are doctors combining B-cell and T-cell therapies? - Management noted that there is potential for combining therapies, and discussions are ongoing regarding the efficacy of such combinations [45][46]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $77.1 million, up 29% from $59.9 million in Q4 2024 [4] - Net product sales of LUPKYNIS for Q4 2025 were $74.2 million, up 29% from $57.6 million in Q4 2024 [4] - Net income for Q4 2025 was $210.8 million, up 14,957% from $1.4 million in Q4 2024 [4] - Diluted earnings per share for Q4 2025 was $1.53, up 15,200% from $0.01 in Q4 2024 [5] - Total revenue for the year ended December 31, 2025, was $283.1 million, up 20% from $235.1 million in 2024 [6] - Net income for the year ended December 31, 2025, was $287.2 million, up 4,852% from $5.8 million in 2024 [6] Business Line Data and Key Metrics Changes - Net product sales of LUPKYNIS for the year ended December 31, 2025, were $271.3 million, up 25% from $216.2 million in 2024 [6] - Cash flows from operating activities for Q4 2025 were $45.7 million, up 52% from $30.1 million in Q4 2024 [5] - Cash flows from operating activities for the year ended December 31, 2025, were $135.7 million, up 206% from $44.4 million in 2024 [7] Market Data and Key Metrics Changes - The company expects net product sales of $305 million to $315 million for 2026, representing a 12%-16% increase compared to 2025 [3][8] - The company repurchased 12.2 million common shares for $98.2 million, reducing fully diluted shares outstanding from 149.8 million to 139.7 million [7][8] Company Strategy and Development Direction - The company is focused on the commercial growth of LUPKYNIS while advancing the clinical development of aritinercept, a novel biologic for autoimmune diseases [9][10] - The strategy includes leveraging data on the efficacy of LUPKYNIS and promoting early diagnosis and treatment of lupus nephritis [14][27] - The company aims to change the treatment paradigm by emphasizing the importance of early identification and aggressive treatment of proteinuria [14][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued growth of LUPKYNIS, citing strong adherence and persistency among patients [24] - The company acknowledged the competitive landscape with the introduction of Gazyva but noted no immediate impact on LUPKYNIS sales [35] - Management emphasized the importance of awareness and aggressive treatment in growing the market for lupus nephritis [36] Other Important Information - The company terminated the phase III VOCAL study due to recruitment challenges and plans to negotiate with the FDA regarding pediatric commitments [16][17] - Management highlighted the potential for combining B-cell and T-cell therapies in treating lupus nephritis, indicating ongoing research in this area [46][47] Q&A Session Summary Question: Guidance for 2026 seems conservative; what are the underlying assumptions? - Management explained that the guidance is based on historical growth patterns and current market conditions, with no extraordinary trends observed in early 2026 [12][15] Question: Clarification on the termination of the VOCAL study and FDA's stance? - Management clarified that the study was terminated due to recruitment difficulties and that they plan to discuss pediatric commitments with the FDA [16][17] Question: Update on aritinercept development and study design? - Management confirmed that a clinical study for aritinercept has been initiated, with more details expected in Q2 2026 [20][22] Question: Impact of Gazyva's approval on LUPKYNIS? - Management stated that there has been no immediate impact on LUPKYNIS sales and that the guidance incorporates various factors, including competition [35][36] Question: Are doctors combining B-cell and T-cell therapies? - Management indicated that there is potential for combining therapies and that they are exploring this in ongoing research [46][47]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $77.1 million, up 29% from $59.9 million in Q4 2024 [3] - Net product sales of LUPKYNIS for Q4 2025 were $74.2 million, up 29% from $57.6 million in Q4 2024 [3] - Net income for Q4 2025 was $210.8 million, up 14,957% from $1.4 million in Q4 2024, primarily due to a significant income tax benefit [3][4] - Diluted earnings per share for Q4 2025 was $1.53, up 15,200% from $0.01 in Q4 2024 [4] - Total revenue for the year ended December 31, 2025, was $283.1 million, up 20% from $235.1 million in 2024 [5] - Net income for the year ended December 31, 2025, was $287.2 million, up 4,852% from $5.8 million in 2024 [5][6] - Cash flows from operating activities for the year ended December 31, 2025, were $135.7 million, up 206% from $44.4 million in 2024 [6] Business Line Data and Key Metrics Changes - Net product sales of LUPKYNIS for the year ended December 31, 2025, were $271.3 million, up 25% from $216.2 million in 2024 [5] - The company repurchased 12.2 million common shares for $98.2 million, reducing fully diluted shares outstanding from 149.8 million to 139.7 million [6][7] Market Data and Key Metrics Changes - The company expects net product sales for 2026 to be between $305 million and $315 million, representing a 12%-16% increase compared to 2025 [2][7] - Total revenue guidance for 2026 is projected to be between $315 million and $325 million, up 11%-15% from 2025 [7] Company Strategy and Development Direction - The company is focused on the growth of LUPKYNIS while advancing the clinical development of aritinercept, a novel biologic for autoimmune diseases [9][10] - The strategy includes leveraging data on the efficacy of LUPKYNIS and promoting early diagnosis and treatment of lupus nephritis [14][27] - The company aims to change the treatment paradigm by emphasizing the importance of early identification and aggressive treatment of proteinuria [14][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued growth of LUPKYNIS, citing strong adherence and persistency among patients [24] - The company acknowledged the competitive landscape with the recent approval of Gazyva but noted no immediate impact on LUPKYNIS sales [34] - Management emphasized the importance of awareness and guideline adoption to improve patient outcomes in lupus nephritis treatment [35][36] Other Important Information - The company has initiated a clinical study of aritinercept in one autoimmune disease and plans to start another study in the first half of 2026 [9][10] - Management indicated that the pediatric lupus nephritis market is small, and the business opportunity in this segment is limited [19] Q&A Session Summary Question: 2026 guidance seems conservative; what are the underlying assumptions? - Management reiterated that the growth strategy for LUPKYNIS remains consistent, focusing on efficacy data and early treatment [12][13] Question: Clarification on the termination of the VOCAL study and FDA interactions? - The VOCAL study was terminated due to recruitment challenges, and the company plans to negotiate with the FDA regarding pediatric commitments [17][18] Question: Update on AURINIAcept development? - Management confirmed that updates on AURINIAcept will be provided in the second quarter of 2026, with no preferential indication at this time [21][22] Question: What is driving the strong performance of LUPKYNIS? - Management noted growth across patients, solid adherence, and a favorable mix of business contributing to continued strong performance [24] Question: Impact of Gazyva's approval on LUPKYNIS? - Management stated that there has been no near-term impact from Gazyva's launch, and guidance incorporates various factors including competition [34][35]

Summary of Key Points from Biotechnology Equity Research Conference Call Industry Overview - The report focuses on the biotechnology sector, specifically highlighting companies with significant potential for growth and upcoming catalysts in 2026. Key Companies and Their Outlook 1. **Dianthus Therapeutics, Inc. (DNTH)** - Market Cap: $1.82 billion - Price Target: $66 - Key catalysts include: - CIDP Phase III interim analysis in Q2 2026 - Initiation of gMG Phase III study in mid-2026 - Phase II MMN topline data in 2H26 - Potential for significant upside based on peak revenue estimates of ~$2 billion across neuromuscular diseases [19][20][24] 2. **Taysha Gene Therapies, Inc. (TSHA)** - Market Cap: $1.50 billion - Price Target: $11 - Focus on pivotal study for TSHA-102 in Rett syndrome with potential for a 6-month interim readout by YE26/1Q27 [26][27] 3. **Tyra Biosciences (TYRA)** - Market Cap: $1.36 billion - Price Target: $32 - Major catalysts include: - Phase III data for achondroplasia in early 2026 - Initial data for IR-NMIBC in 1H26 - Potential to disrupt the market with oral FGFR3 inhibitors [31][35] 4. **Tango Therapeutics, Inc. (TNGX)** - Market Cap: $1.15 billion - Price Target: $14 - Expected to show de-risking data for vopimetostat in combination with RVMD's RAS inhibitors in 2026 [37][40] 5. **ORIC Pharmaceuticals (ORIC)** - Market Cap: $783 million - Price Target: $23 - Key catalysts include dose-optimization data for prostate cancer and validating data from PFE's MEVPRO-1 trial [42][48] 6. **Solid Biosciences (SLDB)** - Market Cap: $463 million - Price Target: $15 - Focus on DMD program with key regulatory feedback expected in 1H26 [49][53] Major Catalysts and Events - **Upcoming Catalysts:** - RARE and MREO Phase III ORBIT final analysis expected in Dec'25/Jan'26 with potential stock movements of +100%/-30% [2] - ALNY, CRSP, and others expected to provide revenue guidance and business plans early in 2026 [1] - Regulatory events including FDA's Rare Disease Day on 2/23/26 [12] - **Drug Launches:** - Expected launches in 2026 include drugs from ALNY, ARWR, KALV, and others targeting various conditions [3] Financial Updates - **Price Target Changes:** - ARWR raised from $67 to $90 - KOD raised from $24 to $39 [6][10] Market Dynamics - **Pricing Stability:** - 2026 net pricing expected to remain stable with current Medicare contracts influencing high gross-to-net (GTN) guidance [12] - **Strategic Interest:** - Potential for M&A activity as companies like ORIC attract interest due to their prostate cancer programs [43] Conclusion - The biotechnology sector is poised for significant developments in 2026, with multiple companies presenting strong investment opportunities based on upcoming catalysts, drug launches, and strategic positioning in the market.

Core Viewpoint - Jefferies recently released a report on the outlook for the U.S. biotech industry in 2026, focusing on preferred investment targets, undervalued potential companies, and potential acquisition opportunities. The report highlights that the biotech sector will see multiple key clinical trial data disclosures, new drug approvals, and policy dynamics, with companies in niche segments expected to achieve value re-evaluation through technological breakthroughs and commercialization progress [1]. Six Preferred Targets - Jefferies identified six companies as core recommendations for 2026 based on market catalysts and valuation potential: - **Dianthus Therapeutics (DNTH.US)**, target price $66: Focused on the drug claseprubart, showing potential in various neuromuscular diseases with an estimated peak revenue of $2 billion. Key milestones include mid-analysis of Phase III trials for CIDP and initiation of trials for gMG in 2026 [3]. - **Taysha Gene Therapies (TSHA.US)**, target price $11: The gene therapy TSHA-102 for Rett syndrome has a market potential of $2 billion. The three-phase clinical trial is expected to disclose mid-term data by the end of 2026 [3]. - **Tyra Biosciences (TYRA.US)**, target price $32: The oral FGFR3 inhibitor dabogratinib has disruptive potential in two areas, with key data expected next year [4]. - **Tango Therapeutics (TNGX.US)**, target price $14: Collaborating with Revolution Medicines to explore a combination therapy for pancreatic cancer, with data expected in the first half of 2026 [4]. - **ORIC Pharmaceuticals (ORIC.US)**, target price $23: Focused on two potential assets for prostate cancer and lung cancer, with key catalysts expected next year [5]. - **Solid Biosciences (SLDB.US)**, target price $15: Concentrating on gene therapy for Duchenne muscular dystrophy, with critical meetings with the FDA planned for 2026 [5]. Seven Undervalued Companies - The report highlights seven companies with significant catalysts and potential for value re-evaluation: - **Ultragenyx Pharmaceutical (RARE.US)**, target price $114: Current stock price undervalued, with key catalysts expected in 2026, including data for treatments of osteogenesis imperfecta and Angelman syndrome [6]. - **Beam Therapeutics (BEAM.US)**, target price $41: Focused on gene editing, with promising data updates expected in early 2026 [6]. - **Aurinia Pharmaceuticals (AUPH.US)**, target price $21: Core product Lupkynis shows steady growth, with new drug development paths expected to be announced in early 2026 [7]. - **Kodiak Sciences (KOD.US)**, target price $39: Potential in retinal disease therapies, with three Phase III trial data readouts expected in 2026 [7]. - **Intellia Therapeutics (NTLA.US)**, target price $45: A leader in gene editing, with key data expected in mid-2026 [8]. - **Compass Therapeutics (CMPX.US)**, target price $8: Focused on tumor bispecific antibodies, with data expected in early 2026 [8]. - **KalVista Pharmaceuticals (KALV.US)**, target price $38: Known for the first oral treatment for hereditary angioedema, with significant revenue growth expected in 2026 [9]. Five Potential Acquisition Targets - Jefferies identified five companies that may become acquisition targets in 2026 due to their unique assets or market positions: - **Arrowhead Pharmaceuticals (ARWR.US)**: Strong RNAi product line for cardiovascular metabolism and new obesity targets [10]. - **Celcuity (CELC.US)**: Drug gedatolisib shows unique efficacy in PIK3CA wild-type breast cancer [11]. - **ORIC Pharmaceuticals**: High-value prostate and lung cancer projects [12]. - **Travere Therapeutics (TVTX.US)**: Potential market opening in rare kidney diseases if FSGS indication is approved [13]. - **KalVista Pharmaceuticals**: First-mover advantage and strong growth in oral HAE drugs [14].

Core Insights - Jefferies recently released a report on the outlook for the U.S. biotech industry in 2026, focusing on preferred investment targets, undervalued potential companies, and potential acquisition opportunities. The report highlights that the biotech sector will see multiple key clinical trial data disclosures, new drug approvals, and policy developments in 2026, with companies in niche segments likely to achieve value re-evaluation through technological breakthroughs and commercialization progress [1]. Preferred Investment Targets - Jefferies identified six core recommended companies for 2026 based on market catalysts and valuation potential: - **Dianthus Therapeutics**: Target price of $66, focusing on the drug claseprubart for various neuromuscular diseases, with peak revenue estimated at $2 billion. Key milestones include mid-analysis of Phase III trials for CIDP and initiation of trials for gMG in 2026 [1]. - **Taysha Gene Therapies**: Target price of $11, with TSHA-102 for Rett syndrome showing significant market potential (peak revenue of $2 billion). Phase III trial data is expected by the end of 2026 [2]. - **Tyra Biosciences**: Target price of $32, with the drug dabogratinib showing disruptive potential in bladder cancer and achondroplasia. Key data is expected next year [2]. - **Tango Therapeutics**: Target price of $14, exploring a combination therapy for pancreatic cancer with expected data release in mid-2026 [2]. - **ORIC Pharmaceuticals**: Target price of $23, with two key assets targeting prostate cancer and lung cancer. Key data updates are anticipated next year [3]. - **Solid Biosciences**: Target price of $15, focusing on gene therapy for Duchenne muscular dystrophy, with critical meetings with the FDA planned for 2026 [3]. Undervalued Companies - The report highlights seven undervalued companies with significant catalysts and potential for value re-evaluation: - **Ultragenyx Pharmaceutical**: Target price of $114, with a current undervalued stock price. Key catalysts include Phase III data for setrusumab expected in late 2025 to early 2026, potentially driving a 100% stock price increase [4]. - **Beam Therapeutics**: Target price of $41, focusing on gene editing with promising data updates expected in early 2026 [5]. - **Aurinia Pharmaceuticals**: Target price of $21, with steady growth in lupus nephritis treatment and new drug development expected to drive growth [5]. - **Kodiak Sciences**: Target price of $39, with three Phase III trial data readouts expected in 2026 [6]. - **Intellia Therapeutics**: Target price of $45, with key data for hereditary angioedema therapy expected in mid-2026 [6]. - **Compass Therapeutics**: Target price of $8, with upcoming data for cholangiocarcinoma therapy expected in early 2026 [6]. - **KalVista Pharmaceuticals**: Target price of $38, with a first-in-class oral treatment for hereditary angioedema expected to drive rapid growth [7]. Potential Acquisition Targets - Jefferies identified five companies that may become acquisition targets in 2026 due to their unique assets or market positions: - **Arrowhead Pharmaceuticals**: Strong RNAi product line in cardiovascular metabolism and new obesity targets [8]. - **Celcuity**: Unique efficacy of gedatolisib in PIK3CA wild-type breast cancer [8]. - **ORIC Pharmaceuticals**: High-value prostate and lung cancer projects [8]. - **Travere Therapeutics**: Potential market expansion in rare kidney diseases if FSGS indication is approved [8]. - **KalVista Pharmaceuticals**: First-mover advantage and strong growth in oral HAE treatment [8].